Psycheceutical Bioscience Inc. Stock Analysis BWVI

Psycheceutical Bioscience, Inc. engages in psychedelic medicine and represents the potential for major progress in the area of mental health treatment. The company is headquartered in Fleming Island, Florida and currently employs 28 full-time employees. The company went IPO on 2007-05-25. The Company’s patented NeuroDirect non-systemic delivery technology is designed to deliver neuro-active compounds directly into the nerve tissue via topical application at the back of the neck. The delivery system is intended to enable immediate and sustained delivery, safe dosage control, and consistent results-while avoiding the GI tract and any unwanted side effects and toxicity. The company has designed a product that improves the quality of life for those suffering from Post-Traumatic Stress Disorder (PTSD) and Chronic Regional Pain Syndrome (CRPS). Its pipeline program includes the PSY-007-KETAMINE. The company focuses on commercializing its precision dosing technologies to provide affordable, life-saving treatments to anyone suffering from mental health disorders or central nervous system diseases.